Last updated on August 2018

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes With a FRC Extension Period


Contact Investigators or Research Sites near you

Start Over

Trial Transparency email recommended (Toll ...

Investigational Site Number 8400063
Houston, TX United States
1.6miles
  Connect »

Trial Transparency email recommended (Toll ...

Investigational Site Number 8400106
Houston, TX United States
1.6miles
  Connect »

Trial Transparency email recommended (Toll ...

Investigational Site Number 8400008
Houston, TX United States
5.93miles
  Connect »